27
Overall Survival (% of patients)
Months
0
3
6
9
12
15
18
0
10
20
30
40
50
60
70
80
90
100
Months
0
3
6
9
12
15
18
0
10
20
30
40
50
60
70
80
90
100
Overall Survival (% of patients)
Nivolumab (n = 63)
Investigator’s Choice (n = 29)
Nivolumab (n = 50)
Investigator’s Choice (n = 36)
HR (95% CI)
0.56 (0.32, 0.99)
HR (95% CI)
0.73 (0.42, 1.25)
p16-Negative
p16-Positive
Nivolumab
Investigator’s
Choice
No. at Risk
63
49
35
0
29
20
11
0
18
4
10
1
3
0
50
32
25
0
36
26
13
0
12
7
6
3
1
1
Overall Survival by p16 Status
Nivolumab in R/M SCCHN After Platinum Therapy
